Table 1 The clinical, pathological, and molecular characteristics of CLDN18.2 positive or negative gastric cancer patients

Age

0.53

 Median, IQR

60 (54–66)

60.5 (54–66)

60 (50–66)

Gender

0.19

 Male

61 (76.3%)

35 (83.3%)

26 (68.4%)

 Female

19 (23.7%)

7 (16.7%)

12 (31.6%)

ECOG PS

> 0.99

 0

49 (61.3%)

26 (61.9%)

23 (60.5%)

 1

31 (38.7%)

16 (38.1%)

15 (39.5%)

Location

0.66

 GEJ

24 (30.0%)

14 (33.33%)

10 (26.3%)

 Non-GEJ

56 (70.0%)

28 (66.67%)

28 (73.7%)

Lauren classification

0.18

 Intestinal type

38 (47.5%)

16 (38.1%)

22 (57.9%)

 Diffused type

18 (22.5%)

12 (28.6%)

6 (15.8%)

 Mixed type

24 (30.0%)

14 (33.3%)

10 (26.3%)

Stage

0.007

 I

3 (3.8%)

1 (2.4%)

2 (5.3%)

 II

9 (11.3%)

0 (0%)

9 (23.7%)

 III

29 (36.2%)

17 (40.5%)

12 (31.6%)

 IV

39 (48.7%)

24 (57.1%)

15 (39.5%)

Differentiation

0.010

 Moderate

23 (28.8%)

6(14.3%)

17 (44.7%)

 Moderate-poor

22 (27.5%)

13(31.0%)

9 (23.7%)

 Poor

35 (43.7%)

23(54.8%)

12 (31.6%)

HER2 expression

0.30

 Positive

22 (27.5%)

9(21.4%)

13 (34.2%)

 Negative

58 (72.5%)

33(78.6%)

25 (65.8%)

PD-L1 expression (CPS)

0.99

 ≥ 10

36 (45.0%)

19 (45.2%)

17 (44.7%)

 5–10

10 (12.5%)

5 (11.9%)

5 (13.2%)

 1–5

17 (21.3%)

9 (21.4%)

8 (21.1%)

 < 1

17 (21.3%)

9 (21.4%)

8 (21.1%)

MMR status

> 0.99

 pMMR

69 (86.3%)

36 (85.7%)

33 (86.8%)

 dMMR

11 (13.7%)

6 (14.3%)

5 (13.2%)

EBV status

0.13

 Positive

10 (12.5%)

8 (19.1%)

2 (5.3%)

 Negative

70 (87.5%)

34 (80.9%)

36 (94.7%)

Treatment

0.12

 Chemotherapy±targeted therapy

20 (25.0%)

14 (33.3%)

6 (15.8%)

 Anti-PD1/PD-L1 based therapy

60 (75.0%)

28 (66.67%)

32 (84.2%)